<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03882983</url>
  </required_header>
  <id_info>
    <org_study_id>CW0001</org_study_id>
    <nct_id>NCT03882983</nct_id>
  </id_info>
  <brief_title>Stromal Vascular Fraction From Lipoaspirate to Treatment of Chronic Non-healing Wound</brief_title>
  <official_title>A Phase I Safety Study Using Stromal Vascular Fraction From Lipoaspirate in the Treatment of Chronic Non-healing Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antria</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Antria</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, open-label, single arm study to demonstrate the safety of Antria Cell&#xD;
      Preparation Process during fat grafting augmented with autologous adipose derived stromal&#xD;
      vascular fraction to demonstrate the safety and efficacy of administration of SVF enriched&#xD;
      fat grafting in chronic wounds&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I, open-label, single arm study to demonstrate the safety of Antria Cell&#xD;
      Preparation Process during fat grafting augmented with autologous adipose derived stromal&#xD;
      vascular fraction to demonstrate the safety and efficacy of administration of SVF enriched&#xD;
      fat grafting in chronic wounds.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bates-Jensen Wound Assessment</measure>
    <time_frame>1 year</time_frame>
    <description>This assessment focuses on analysis wounds with regards to the following information: size, depth, edges, undermining, necrotic tissue type, necrotic tissue amount, exudate type, exudate amount, skin color surrounding the wound, peripheral tissue edema and induration, granulation tissue, and epithelialization. Each item will be measured on a scale 1-5. A score of 1 will indicate least severe and a score of 5 will indicate the most severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Digital Picture of wound</measure>
    <time_frame>1 year</time_frame>
    <description>Digital pictures of subject's wounds pre-treatment and post-treatment will be performed to show changed from baseline assessments.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Wounds</condition>
  <arm_group>
    <arm_group_label>Antria Cell Preparation Process</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Safety will be evaluated by collection of vital signs, EKG, patient surveys, and assessments</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antria Cell Preparation Process</intervention_name>
    <description>Biological/Vaccine: Stromal Vascular Fraction The SVF obtained from adipose tissue will be added to the graft&#xD;
Other Names:&#xD;
Stromal Vascular Fraction&#xD;
Adiployx Biological/Vaccine:</description>
    <arm_group_label>Antria Cell Preparation Process</arm_group_label>
    <other_name>SVF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female or Male, Age 18 years or older&#xD;
&#xD;
          2. Subjects that are diagnosed with one or more chronic wounds.&#xD;
&#xD;
          3. Able to understand and provide written and verbal informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Currently taking or have taken NSAIDs within last two weeks or corticosteroids within&#xD;
             the last six weeks prior to screening.&#xD;
&#xD;
          2. Diagnosis of any of the following medical conditions:&#xD;
&#xD;
               -  Active malignancy (diagnosed within 5 years), except for treated non-melanoma&#xD;
                  skin cancer or other non-invasive or in-situ neoplasm (e.g. cervical cancer)&#xD;
&#xD;
               -  Active infection (other than their wound)&#xD;
&#xD;
          3. Subjects who are unlikely to comply with the protocol (e.g., uncooperative attitude,&#xD;
             inability to return for subsequent visits, dementia, and/or otherwise considered by&#xD;
             the Investigator to be unlikely to complete the study)&#xD;
&#xD;
          4. Subjects with a known drug or alcohol dependence within the past 12 months as judged&#xD;
             by the Investigator&#xD;
&#xD;
          5. Any other disease condition or laboratory results that in the opinion of the&#xD;
             investigator may be clinically significant and render the subject inappropriate for&#xD;
             the study procedure(s), may alter the accuracy of study results, or increase the risk&#xD;
             for subjects.&#xD;
&#xD;
          6. Subjects with life-expectancies less than 12 months&#xD;
&#xD;
          7. Subjects with known collagenase allergies&#xD;
&#xD;
          8. Pregnant females On radiotherapy or chemotherapy agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonard E Maliver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antria Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leonard E Maliver, MD</last_name>
    <phone>7243490520</phone>
    <phone_ext>7243490520</phone_ext>
    <email>lmaliver@antria.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah C Boyer, MS, MA</last_name>
    <phone>7243490520</phone>
    <phone_ext>7243490520</phone_ext>
    <email>sboyer@antria.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana Regional Medical Center</name>
      <address>
        <city>Indiana</city>
        <state>Pennsylvania</state>
        <zip>15701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonard E Maliver, MD</last_name>
      <phone>724-349-0520</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 24, 2017</study_first_submitted>
  <study_first_submitted_qc>March 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2019</study_first_posted>
  <last_update_submitted>March 18, 2019</last_update_submitted>
  <last_update_submitted_qc>March 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autologous Adult Stem Cell</keyword>
  <keyword>Lipoaspirate</keyword>
  <keyword>Non-healing Wounds</keyword>
  <keyword>Stomal Vasular Fraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

